ArticleTranslational cancer research2025
Transarterial chemoembolization in combination with lenvatinib and sintilimab for the treatment of unresectable hepatocellular carcinoma with arterioportal shunts: a retrospective analysis.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The efficacy of transarterial chemoembolization (TACE) in treating unresectable hepatocellular carcinoma (uHCC) complicated by arterioportal shunts (APS) was unsatisfactory. Developed systemic therapies can synergize with TACE, potentially reducing APS recanalization and enhancing patient benefits. The objective of this study was to evaluate and compare the therapeutic efficacy and safety of a combination therapy regimen that includes TACE, lenvatinib, and sintilimab (TACE-L-S) versus TACE monotherapy in uHCC patients with APS. Methods: After reviewing hospital records, this retrospective study enrolled 96 patients: 51 in the TACE-L-S group and 45 in the TACE group. We utilized the Chi-squared test to analyze tumor response, changes in APS grades, APS recanalization rates, and adverse events (AEs) between the two groups. Kaplan-Meier analysis was employed to compare median progression-free survival (mPFS). Cox regression analyses were conducted to identify factors influencing mPFS, whereas logistic regression analyses were performed to assess factors influencing APS recanalization rates. Results: The objective response rate (ORR) was 68.6% in the TACE-L-S group and 37.8% in the TACE group (P=0.002). The TACE-L-S group had better mPFS compared to the TACE group (168 Conclusions: For uHCC patients with APS, TACE-L-S may be a kind of effective and safe therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.